Arbutus Biopharma (ABUS) Interest & Investment Income (2013 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Interest & Investment Income of $815000.0 for Q1 2026, down 31.91% year-on-year from $1.2 million in Q1 2025, and down 7.07% on a QoQ basis from $877000.0 in Q4 2025.
Arbutus Biopharma (ABUS) Interest & Investment Income (2013 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Interest & Investment Income for 14 consecutive years, with $815000.0 the latest figure, recorded in Q1 2026.
- Quarterly Interest & Investment Income fell 31.91% year-over-year to $815000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (down 40.9% YoY) and the FY2025 annual result came in at $4.1 million, down 38.22% from the prior year.
- Interest & Investment Income eased to $815000.0 in Q1 2026 per ABUS's latest filing, from $877000.0 in the prior quarter.
- Over the last five years, Interest & Investment Income for ABUS reached as high as $1.8 million in Q2 2024 and fell as low as $159000.0 in Q1 2022.
- A 5-year average of $1.1 million and a median of $1.2 million in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 3043.33% — and 2025, when it slumped 45.51%.
- Year by year, Interest & Investment Income stood at $943000.0 in 2022, then soared by 55.36% to $1.5 million in 2023, then dropped by 0.07% to $1.5 million in 2024, then tumbled by 40.1% to $877000.0 in 2025, then fell by 7.07% to $815000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $815000.0, $877000.0, and $952000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Arbutus Biopharma | 862.27 Mn | 767.04 Mn | - | 815,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 815,000.00 |
| Dec 31, 2025 | 877,000.00 |
| Sep 30, 2025 | 952,000.00 |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Jun 30, 2023 | 1.46 Mn |
| Mar 31, 2023 | 1.27 Mn |
| Dec 31, 2022 | 943,000.00 |
| Sep 30, 2022 | 694,000.00 |
| Jun 30, 2022 | 396,000.00 |
| Mar 31, 2022 | 159,000.00 |
| Dec 31, 2021 | 30,000.00 |
| Sep 30, 2021 | 27,000.00 |
| Jun 30, 2021 | 31,000.00 |